Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2006 Oct;2(4):287-93.
doi: 10.1016/j.jalz.2006.05.2347.

Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease." Biochemical biomarkers of late-life dementia

Christopher M Clark  1 , Domenico Pratico, Lesley M Shaw, Susan Leight, Sharon X Xie, Amy Gu, Virginia M-Y Lee, John Q Trojanowski
Affiliations
Comment

Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease." Biochemical biomarkers of late-life dementia

Christopher M Clark et al. Alzheimers Dement. 2006 Oct.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
CSF total tau in controls and autopsy-proven AD.
Fig. 2
Fig. 2
Correlation of total tau with p-tau 181 in CSF of patients with AD.
Fig. 3
Fig. 3
F2 isoprostane in frontal lobes of patients with Alzheimer’s disease, frontal dementia, and controls.
Fig. 4
Fig. 4
CSF F2 isoprostane in patients with autopsy confirmed Alzheimer’s disease and cognitively normal subjects.
Fig. 5
Fig. 5
Urine F2 isoprostanes in patients with Alzheimer’s disease, frontal dementia, and control subjects.
Fig. 6
Fig. 6
Correlation of F2 isoprostane in CSF and urine of patients with Alzheimer’s disease.
See this image and copyright information in PMC

Comment on

References

    1. Forman MS, Farmer J, Johnson JK, Clark CM, Arnold SE, Coslett HB, et al. Frontotemporal dementia: Clinicopathological correlations. Ann Neurol. 2006 (In press) - PMC - PubMed
    1. Grossman M, Farmer J, Leight S, Work M, Moore P, Van DV, et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease. Ann Neurol. 2005;57(5):721–9. - PubMed
    1. Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, et al. Biological markers for therapeutic trials in Alzheimer’s disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer’s disease Neurobiol Aging. 2003;24(4):521–36. - PubMed
    1. Blennow K, Vanmechelen E, Hampel H. CSF total tau, Ab42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease. Mol Neurobiol. 2001;24(1–3):87–97. - PubMed
    1. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003 Dec;60(12):1696–702. - PubMed